ClinConnect ClinConnect Logo
Search / Trial NCT04889053

Coronary Artery Calcification in Type 2 Diabetes Mellitus (USCAC Study)

Launched by UNIVERSITY OF SOUTH CHINA · May 11, 2021

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Type 2 Diabetes Vascular Calcification Epidemiology Micro Rna 32

ClinConnect Summary

The USCAC Study is a clinical trial that aims to understand the issue of coronary artery calcification (CAC) in people with type 2 diabetes. CAC is a condition where calcium builds up in the arteries, which can lead to serious heart problems and increase the risk of death. This study will look at how common CAC is among type 2 diabetes patients in Hunan province, how statin medications may affect it, and whether a specific molecule called miR-32 could help with early diagnosis. The researchers hope that their findings will lead to better prevention and treatment strategies for patients with both diabetes and coronary artery calcification.

To participate in this study, individuals need to be at least 18 years old and diagnosed with type 2 diabetes. They must also be able to undergo a specific type of heart scan. However, people who have had certain heart surgeries, have severe health issues, or are pregnant cannot join the study. Participants will be monitored closely throughout the trial, and their experiences may contribute valuable information to improve heart health in people living with diabetes.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years old
  • Type 2 diabetes is diagnosed according to WHO diagnostic criteria
  • Low dose prospectively triggered sequential dual-source CT coronary angiography can be performed at baseline investigation
  • Those subjects are able to understand the purpose and procedure of this study and sign the informed consent voluntarily
  • Exclusion Criteria:
  • Those have received coronary artery stenting or coronary artery bypass grafting
  • Those with severe lung (respiratory failure), liver (ALT or AST 3 times normal value or bilirubin increase), renal dysfunction\[GFR \< 45ml/(min.1.73m2) or dialysis patients
  • Malignant tumor
  • Mental illness or mental retardation
  • Pregnant or lactating women or those with fertility planning
  • Concomitant diseases (hyperparathyroidism, sarcoidosis, amyloidosis) affecting calcium balance and soft tissue calcification
  • Contraindications of contrast agents
  • Based on the judgment of the researcher, the compliance is poor and the study could not be completed according to the requirements

About University Of South China

The University of South China is a leading academic institution dedicated to advancing medical research and clinical innovation. With a strong emphasis on interdisciplinary collaboration, the university fosters a dynamic environment for conducting clinical trials that aim to enhance patient care and improve health outcomes. The institution is committed to adhering to the highest ethical standards and regulatory requirements while engaging in groundbreaking studies across various medical fields. By leveraging its robust network of healthcare professionals and researchers, the University of South China strives to contribute significantly to the global body of medical knowledge and the development of effective treatments.

Locations

Hengyang, , China

Patients applied

0 patients applied

Trial Officials

Liu Jianghua, PhD

Study Chair

The First Affiliated Hospital of University of South China

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials